Literature DB >> 15320841

Platelet activation, inflammatory mediators and hypercholesterolemia.

Patrizia Ferroni1, Stefania Basili, Giovanni Davi.   

Abstract

Atherogenic cofactors, such as altered cholesterol metabolism, may impact locally on inflammatory responses in atherosclerotic lesions. Blood levels of inflammatory markers (e.g., C-reactive protein, fibrinogen) have been associated with hypercholesterolemia and with overt atherothrombotic disorders. More recently. cytokines (e.g., interleukin-6, interleukin-1beta) and soluble adhesion molecules (e.g., selectins, intercellular adhesion molecule-1, vascular cell adhesion molecule-1) have been associated with both hypercholesterolemia and atherosclerotic disease, suggesting their use as potential therapeutic targets for the non-specific "anti-inflammatory" treatment of atherosclerosis. The inflammatory response associated with hypercholesterolemia involves not only the intrinsic cells of the artery wall. but also circulating cells. Platelets participate in this disease process through the release of a wide variety of biologically active substances. An imbalance of the hemostatic system and persistent in vivo platelet activation can be observed in hypercholesterolemia and may have pathophysiological implications in the development and progression of atherosclerotic plaques. Recent findings on the inflammatory actions of platelets have established the potential for a previously unrecognized biologic role for platelets in inflammation and vascular injury, and have opened new perspectives in the comprehension of the pathogenetic mechanism(s) of atherosclerosis. Stimulated platelets actively synthesize proinflammatory cytokines (e.g., CD40L, IL-1beta) and are able to release chemokines (i.e., platelet factor-4, RANTES) which have been all involved in the inflammatory process associated with hypercholesterolemia. This review will summarize the present understanding of the interplay between hypercholesterolemia, inflammation and platelet activation in the development and progression of atherosclerosis, and we also discuss the effects of lipid-lowering treatment on these phenomena.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15320841     DOI: 10.2174/1570161033476772

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  21 in total

1.  A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters.

Authors:  Vishal Singh; Manish Jain; Prem Prakash; Ankita Misra; Vivek Khanna; Rajiv Lochan Tiwari; Ravi Shankar Keshari; Shivendra Singh; Madhu Dikshit; Manoj Kumar Barthwal
Journal:  J Physiol Biochem       Date:  2011-02-01       Impact factor: 4.158

2.  Functional expression of IgA receptor FcalphaRI on human platelets.

Authors:  Kun Qian; Fenglong Xie; Andrew W Gibson; Jeffrey C Edberg; Robert P Kimberly; Jianming Wu
Journal:  J Leukoc Biol       Date:  2008-09-10       Impact factor: 4.962

3.  Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia.

Authors:  B Nagy; J Jin; B Ashby; M P Reilly; S P Kunapuli
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

4.  Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4.

Authors:  K Aneja; G Jalagadugula; G Mao; A Singh; A K Rao
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

Review 5.  Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain.

Authors:  Young-Kook Kim; Juhyun Song
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

6.  The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.

Authors:  Thomas Schöndorf; Petra B Musholt; Cloth Hohberg; Thomas Forst; Ute Lehmann; Winfried Fuchs; Mirjam Löbig; Jürgen Müller; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2011-03-01

7.  Relationship between Mean Platelet Volume and Critical Limb Ischemia in Diabetes Mellitus Patients.

Authors:  Muhammad Berian Rachmanadi; Muhamad Taufik Ismail; Vita Yanti Anggraeni
Journal:  Int J Angiol       Date:  2021-04-20

8.  Gender dependence for a subset of the low-abundance signaling proteome in human platelets.

Authors:  Ofer Eidelman; Catherine Jozwik; Wei Huang; Meera Srivastava; Stephen W Rothwell; David M Jacobowitz; Xiaoduo Ji; Xiuying Zhang; William Guggino; Jerry Wright; Jeffrey Kiefer; Cara Olsen; Nima Adimi; Gregory P Mueller; Harvey B Pollard
Journal:  Hum Genomics Proteomics       Date:  2010-04-13

9.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

10.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.